MBA, PhD, is the Chief Executive Officer of The Parker Institute for Cancer Immunotherapy (PICI — https://www.parkerici.org/), a 501c3 nonprofit organization driving the next generation of cancer treatment by accelerating the development of breakthrough immune therapies to turn all cancers into curable diseases.

Dr. Knudsen most recently served as the Chief Executive Officer of the American Cancer Society (ACS) and ACS Cancer Action Network (ACS CAN), where she led both organizations through a period of transformative growth, significantly expanding research investments, advocacy reach, and direct patient support initiatives. Under her leadership, ACS evolved into a unified, high-performing enterprise, increasing revenue by more than 30 percent and broadening its impact to serve over 55 million lives annually. Moreover, Dr. Knudsen developed and scaled innovative programs that included joint ventures and an impact innovation arm to accelerate progress against cancer.

Prior to ACS, Dr. Knudsen served as Executive Vice President of Oncology Services at Jefferson Health and Enterprise Director of the Sidney Kimmel Comprehensive Cancer Center, growing a multi-state oncology network and spearheading advancements in translational cancer research that increased early access to the most advanced cancer care.

A globally recognized expert in prostate cancer, Dr. Knudsen has authored over 200 scientific publications and generated practice-changing discoveries.

Dr. Knudsen held leadership roles with organizations including the National Cancer Institute Board of Scientific Advisors, the Association of American Cancer Institutes, and the American Association for Cancer Research. She currently serves on the boards of Exai Bio, Paradigm Health, and Research!America, and advises multiple biotech ventures including ArteraAI and Transcarent.

Dr. Knudsen holds numerous awards for her scientific and healthcare accomplishments, and this year will be honored with the Allen Lichter Visionary Leader Award from the American Society of Clinical Oncology (ASCO), recognizing her lifetime achievement of outstanding contributions to the field of oncology.

A 2018 review became the first meta-analysis to quantify the impact of what they termed “greenspace exposure”. It sifted through five online databases leading up to January 2017 to look at the health outcomes of exposure to the great outdoors and found that “green prescriptions” could have substantial benefits to human health.

Perks mentioned included decreased salivary cortisol (the “stress hormone”), lower heart rate, blood pressure, and cholesterol, among others.

“Incidence of stroke, hypertension, dyslipidaemia, asthma, and coronary heart disease were reduced,” wrote the authors. “For several non-pooled health outcomes, between 66.7% and 100% of studies showed health-denoting associations with increased greenspace exposure, including neurological and cancer-related outcomes, and respiratory mortality.”

Researchers have provided new insights into how exercise helps lose weight. They discovered a mechanism by which the compound Lac-Phe, which is produced during exercise, reduces appetite in mice, leading to weight loss. The findings appeared in Nature Metabolism.

“Regular exercise is considered a powerful way to lose weight and to protect from obesity-associated diseases, such as diabetes or heart conditions,” said co-corresponding author Dr. Yang He, assistant professor of pediatrics—neurology at Baylor and investigator at the Duncan NRI. “Exercise helps lose weight by increasing the amount of energy the body uses; however, it is likely that other mechanisms are also involved.”

The researchers previously discovered that Lac-Phe is the most increased metabolite—a product of the body’s metabolism—in blood after intense exercise, not just in mice but also in humans and racehorses. The team’s previous work showed that giving Lac-Phe to obese mice reduced how much they ate and helped them lose weight without negative side effects. But until now, scientists didn’t fully understand how Lac-Phe works to suppress appetite.

Mortality after emergency abdominal surgery is more than three times higher in the least developed countries compared to the most developed. Yet among those who undergo surgery, injuries tend to be less severe—raising concerns that those most critically injured are not even reaching the operating theater.

A study published in The Lancet Global Health has revealed stark global inequalities in survival after emergency abdominal surgery for traumatic injuries. The research found that patients in the world’s least developed countries face a substantially higher risk of dying within 30 days of surgery than those in the most developed nations, as ranked by the United Nations Human Development Index (HDI).

Although overall mortality rates appeared similar across settings at 11%, risk-adjusted analysis showed that patients in the lowest-HDI countries faced more than three times the risk of death compared with those in the highest-HDI group, while the risk in middle-HDI countries was nearly double.